Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Managing antiphospholipid syndrome in pregnancy

    Research output: Contribution to journalReviewResearchpeer-review

  5. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Adriano Alatri
  • Anna-Elina Armstrong
  • Andreas Greinacher
  • Andreas Koster
  • Sibylle A Kozek-Langenecker
  • Marcus D Lancé
  • Andreas Link
  • Jørn D Nielsen
  • Per M Sandset
  • Alexander J Spanjersberg
  • Michael Spannagl
View graph of relations
Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.
Original languageEnglish
JournalThrombosis Research
Volume129
Issue number4
Pages (from-to)426-33
Number of pages8
ISSN0049-3848
DOIs
Publication statusPublished - 2012

    Research areas

  • Anticoagulants, Antithrombins, Dose-Response Relationship, Drug, Europe, Hematology, Heparin, Humans, Pipecolic Acids, Practice Guidelines as Topic, Thrombocytopenia, Treatment Outcome

ID: 36764745